Stay updated on Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:50:01.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has undergone significant changes, including the removal of detailed study information regarding the safety and clinical activity of nivolumab and relatlimab in treating MSS colorectal cancer, as well as the deletion of specific inclusion and exclusion criteria for participants. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.
    Difference
    24%
    Check dated 2025-04-16T01:45:23.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 28, 2025.
    Difference
    0.7%
    Check dated 2025-04-08T20:23:19.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-03-03T22:14:34.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T09:30:30.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    The study has posted results for three cohorts of colorectal cancer patients, detailing the CPM score criteria for treatment eligibility and the administration of Nivolumab and Relatlimab, while removing previous references to active recruitment and specific drug administration details.
    Difference
    31%
    Check dated 2025-02-03T05:43:48.000Z thumbnail image

Stay in the know with updates to Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MSS Colorectal Cancer Clinical Trial page.